MediciNova Inc
NASDAQ:MNOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MediciNova Inc
Other Long-Term Assets
MediciNova Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MediciNova Inc
NASDAQ:MNOV
|
Other Long-Term Assets
$19k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-15%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$10.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
25%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$6.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$12.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
35%
|
CAGR 10-Years
64%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$5.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
44%
|
CAGR 10-Years
29%
|
|
MediciNova Inc
Glance View
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company is headquartered in La Jolla, California and currently employs 11 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. The company is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The firm's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
See Also
What is MediciNova Inc's Other Long-Term Assets?
Other Long-Term Assets
19k
USD
Based on the financial report for Dec 31, 2025, MediciNova Inc's Other Long-Term Assets amounts to 19k USD.
What is MediciNova Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-15%
Over the last year, the Other Long-Term Assets growth was 0%. The average annual Other Long-Term Assets growth rates for MediciNova Inc have been -43% over the past three years , -38% over the past five years , and -15% over the past ten years .
